60 documents

Read All
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
Read More
21:44 , Oct 10, 2018 |  BC Extra  |  Politics & Policy

China adds insurance coverage for 17 cancer therapies

China's National Medical Insurance Administration added 17 cancer drugs to the National Reimbursement Drug List (NRDL) for coverage by the country's medical insurance program. The prices will go into effect by the end of October...
Read More
20:34 , Aug 17, 2018 |  BC Extra  |  Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
Read More
22:35 , Jun 25, 2018 |  BC Extra  |  Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
Read More
23:10 , Mar 21, 2017 |  BC Extra  |  Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
Read More
01:01 , Feb 25, 2017 |  BioCentury  |  Finance

Intranasal option

Canaan Partners sees a clear market opportunity for a non-invasive somatostatin analog, prompting the VC to lead a $25 million series A extension for Dauntless Pharmaceuticals Inc. The financing, announced Feb. 16, brings the round's...
Read More
01:19 , Jan 14, 2017 |  BC Extra  |  Company News

Management tracks

Rare diseases company Swedish Orphan Biovitrum AB (SSE:SOBI) said CEO Geoffrey McDonough will leave the company on July 1. The company is searching for a replacement. The company also named Armin Reininger SVP and head...
Read More
07:00 , Oct 6, 2016 |  BC Extra  |  Company News

Management tracks

Chiasma Inc. (NASDAQ:CHMA) said President and CEO Mark Leuchtenberger left the endocrine company. CFO Mark Fitzpatrick will succeed him. Oncology company BeiGene Ltd. (NASDAQ:BGNE) named Ross Pettit SVP of global development operations. He was SVP...
Read More
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
Read More
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Chiasma endocrine/metabolic news

Chiasma will reduce headcount by about 44% to less than 25 in its second wave of reductions since FDA issued a complete response letter in April to an NDA for Mycapssa octreotide ( RG3806 )...
Read More